Federico Camilli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Federico Camilli has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Lancia
Department of Radiation Oncology, Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy
1 shared publication - Beatrice Detti
Radiotherapy Unit Prato, Usl Centro Toscana, Presidio Villa Fiorita, 59100 Prato, Italy
1 shared publication - David Alberto Santos Hernandez
Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
1 shared publication - Eleonora Festa
Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, 06156 Perugia, Italy
1 shared publication - Elisabetta Bonzano
Department of Radiation Oncology, IRCCS San Matteo Polyclinic Foundation, 27100 Pavia, Italy
1 shared publication - Emanuele Alì
Radiation Oncology Unit, Azienda USL-Istituto di Ricovero e Cura a Carattere Scientifico Di Reggio Emilia, 42123 Reggio Emilia, Italy
1 shared publication
Latest Publications
- Open Access
- 8 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1697
Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer
Prostate cancer (PCa) is the second most common cancer in men, and it is frequently diagnosed at an advanced stage of the disease. Androgen Deprivation Therapy (ADT) has traditionally represented the backbone of therapy for high-risk, recurrent, and metastatic disease; however, in the last ten years a new group of molecules known as androgen receptor pathway inhibitors (ARPIs) have been demonstrated to improve outcomes in metastatic patients when added to ADT. Developed and validated originally in the setting of castration-resistant disease, ARPIs have been implemented progressively earlier in the natural history of PCa, involving patients who have never received ADT before or that are still responsive to this treatment. Considering the strong evidence for treatment intensification in patients with high-risk features, with this review we aim to provide a complete overview of the current indications for the use of ARPIs through all the stages of castration-sensitive prostate cancer (CSPC).
- 8 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1697
Open AccessRecent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer
Prostate cancer (PCa) is the second most common cancer in men, and it is frequently diagnosed at an advanced stage of the disease. Androgen Deprivation Therapy (ADT) has traditionally represented the backbone of therapy for high-risk, recurrent, and metastatic disease; however, in the last ten years a new group of molecules known as androgen receptor pathway inhibitors (ARPIs) have been demonstrated to improve outcomes in metastatic patients when added to ADT. Developed and validated originally in the setting of castration-resistant disease, ARPIs have been implemented progressively earlier in the natural history of PCa, involving patients who have never received ADT before or that are still responsive to this treatment. Considering the strong evidence for treatment intensification in patients with high-risk features, with this review we aim to provide a complete overview of the current indications for the use of ARPIs through all the stages of castration-sensitive prostate cancer (CSPC).